[Using carboxymethl starch sodium solution for the treatment of children with cough variation asthma]

To analysis the clinical characteristics of children with cough variation asthma (CVA) who received treatments with Carboxymethl starch sodium solution and inhaled Glucocorticoid budesonide.

A total of 96 children with CVA were divided into two group randomly. The control group (n = 49) received inhaled budesonide treatment (500 microg/times in 1-5 years old children, 1 mg/times and 2 times/day in 6-14 years old children over a 12 week period). The children in treatment group (n = 47) were given carboxymethl starch sodium solution (3 mL/times in 1-3 years old children, 5 mL/times in 4-7 years old children, 7 mL/times in 8-14 years old children, 3 times/day) in addition to the inhaled budesonide treatment. Observations were made on clinical therapeutic effects, cough score and the level of IgE 4 weeks, 8 weeks and 12 weeks after the treatments, respectively. Recurrence rate and adverse reactions were investigated.

Compared with the control group, the treatment group had significantly improved clinical characteristics after 8 weeks and 12 weeks of treatments (P < 0.05), and reduced cough scores after 4 weeks, 8 weeks and 12 weeks of treatments (P< 0.05). The IgE level of the children in the treatment group was significantly lower than the controls after 12 weeks of treatments (P < 0.05). The treatment group also had significantly lower recurrence rate and adverse reactions than the controls (P < 0.05).

Carboxymethl starch sodium solution can boost the clinical efficiency of inhaled budesonide in the treatment of children with cough variant asthma. It is safe and effectual.